"We are extremely pleased to have attracted such a high-quality group of investors," said Epiphany CEO Fred Volinsky, MD. "Epiphany has assembled one of the finest virology teams in life science today, a group that includes our Chief Scientific Officer Michael Houghton, PhD, Chief Medical officer Brian Murphy, MD, MBA, co-founder Robert Gallo, MD, and Scientific Advisory Board members Drs. Roger Kornberg, Hans Wigzell, Yuan Chang, Patrick Moore, and other eminent scientists and clinicians," noted Volinsky. "The funding will enable us to advance our lead programs including our anti-viral drug candidate Valomaciclovir (EPB-348) through Phase 2b clinical trials against shingles as well as Epiphany's development of HHV-8/KSHV screening diagnostics," added David Myles, PhD, COO.
Epiphany is committed to bringing life-improving therapeutics and diagnostics to patients suffering from chronic and debilitating conditions caused by infectious agents.
About Epiphany Biosciences
Epiphany Biosciences is focused on advancing new therapies for infectious disease. Epiphany's founding team includes a world class group of virologists as well as several Albert Lasker award winners. The founders of Epiphany Biosciences include Fred Volinsky MD, Robert Gallo MD, David Myles PhD, Barry Selick PhD, and Lee Meisel MD, JD, MPH. Epiphany is located in San Francisco, CA. Additional information on Epiphany Biosciences may be obtained at the company website www.epiphanybio.com or by contacting company representatives: Fred G. Volinsky MD, CEO 415.765.7193; David C. Myles PHD, COO 415.765.7198.
Source: Epiphany Biosciences
